Astellas Pharma Inc. Site Map
 
Home > News Room > News Releases
   
News Releases

February 27, 2013

AVEO AND ASTELLAS ANNOUNCE FDA ADVISORY COMMITTEE TO REVIEW TIVOZANIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

February 26, 2013

MEDIVATION AND ASTELLAS PROVIDE ADDITIONAL SUPPORT TO METASTATIC PROSTATE CANCER PATIENTS THROUGH DONATIONS TO INDEPENDENT NON-PROFIT PATIENT ASSISTANCE ORGANIZATION

February 19, 2013

HUMANA AND ASTELLAS FORM RESEARCH COLLABORATION TO IMPROVE HEALTH CARE DELIVERY FOR SENIORS

February 19, 2013

ASTELLAS TO DRIVE PGA TOUR’S NEW WOMEN’S INITIATIVE

February 13, 2013

ASTELLAS HIGHLIGHTS PROGRESS TO ADVANCE CARE OF PATIENTS WITH GENITOURINARY CANCERS AT ASCO-GU ANNUAL MEETING

February 13, 2013

ENZALUTAMIDE DATA PRESENTED AT ASCO GU SYMPOSIUM

February 12, 2013

AVEO AND ASTELLAS REPORT FINAL OVERALL SURVIVAL RESULTS FROM TIVO-1

January 30, 2013

ENZALUTAMIDE DATA TO BE PRESENTED AT ASCO GU SYMPOSIUM

January 30, 2013

AVEO AND ASTELLAS ANNOUNCE PRESENTATIONS OF TIVOZANIB CLINICAL DATA AT 2013 ASCO GENITOURINARY CANCERS SYMPOSIUM

January 22, 2013

ASTELLAS’ NEW HEADQUARTERS FOR THE AMERICAS AWARDED LEED GOLD CERTIFICATION

January 16, 2013

FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR TARCEVA® (ERLOTINIB) TABLETS FOR GENETICALLY DISTINCT FORM OF ADVANCED LUNG CANCER

January 10, 2013

AGENSYS CELEBRATES OPENING OF NEW FACILITY IN SANTA MONICA

December 04, 2012

ASTELLAS ANNOUNCES ACCEPTANCE OF U.S. NEW DRUG APPLICATION FOR TACROLIMUS EXTENDED RELEASE CAPSULES

December 03, 2012

AVEO AND ASTELLAS ANNOUNCE INITIATION OF PATIENT ENROLLMENT IN PHASE 2 TRIAL OF TIVOZANIB IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED TRIPLE NEGATIVE BREAST CANCER

November 28, 2012

AVEO AND ASTELLAS ANNOUNCE FDA ACCEPTANCE OF NDA FILING FOR TIVOZANIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

November 20, 2012

ASTELLAS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR TARCEVA® AS A FIRST-LINE THERAPY IN GENETICALLY DISTINCT FORM OF NON-SMALL CELL LUNG CANCER

November 01, 2012

ASTELLAS APPOINTS NEW VICE PRESIDENT OF SCIENTIFIC AND MEDICAL AFFAIRS

October 22, 2012

MYRBETRIQ™ (MIRABEGRON), OVERACTIVE BLADDER TREATMENT FROM ASTELLAS, NOW AVAILABLE THROUGH U.S. PHARMACIES

October 11, 2012

ASTELLAS ANNOUNCES COMPLIANCE OFFICER FOR THE AMERICAS

October 02, 2012

ASTELLAS PHARMA US RECEIVES CEO CANCER GOLD STANDARD ACCREDITATION

October 01, 2012

AVEO AND ASTELLAS ANNOUNCE NEW DATA PRESENTED AT ESMO 2012 CONGRESS DEMONSTRATING THE SAFETY AND TOLERABILITY PROFILE OF TIVOZANIB IN PATIENTS WITH ADVANCED KIDNEY CANCER

September 30, 2012

MEDIVATION AND ASTELLAS ANNOUNCE NEW DATA FROM XTANDI® (ENZALUTAMIDE) PIVOTAL STUDY

September 28, 2012

AVEO AND ASTELLAS ANNOUNCE SUBMISSION OF NEW DRUG APPLICATION FOR TIVOZANIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

September 24, 2012

ASTELLAS SUBMITS U.S. NEW DRUG APPLICATION FOR TACROLIMUS EXTENDED RELEASE CAPSULES, A PROPHYLAXIS OF ORGAN REJECTION IN TRANSPLANT RECIPIENTS

September 14, 2012

PERSONAL CONNECTIONS DRIVE EMPLOYEE PARTICIPATION FOR CHANGING TOMORROW DAY AT ASTELLAS

September 13, 2012

MEDIVATION AND ASTELLAS ANNOUNCE XTANDI® (ENZALUTAMIDE) IS NOW AVAILABLE FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL

August 31, 2012

PATIENT INFORMATION XTANDI® (EX TAN DEE)(ENZALUTAMIDE) CAPSULES

August 31, 2012

FULL PRESCRIBING INFORMATION FOR XTANDI® (ENZALUTAMIDE) CAPSULES

August 31, 2012

U.S. FDA APPROVES XTANDI® (ENZALUTAMIDE) AFTER PRIORITY REVIEW FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXE

August 15, 2012

NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES RESULTS FROM PHASE 3 AFFIRM TRIAL OF ENZALUTAMIDE

August 06, 2012

ASTELLAS TO CLOSE UROGENIX, NORTH CAROLINA-BASED UROLOGY RESEARCH FACILITY

August 03, 2012

MEDIVATION AND ASTELLAS ANNOUNCE PDUFA ACTION DATE FOR ENZALUTAMIDE NDA

July 25, 2012

ASTELLAS AND FUJITA HEALTH UNIVERSITY DISCOVER NEURONAL MATURATION DEFICITS IN PATIENTS SUFFERING FROM SCHIZOPHRENIA AND BIPOLAR DISORDER

July 24, 2012

ENZALUTAMIDE GRANTED PRIORITY REVIEW BY U.S. FDA FOR THE POTENTIAL TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER IN PATIENTS PREVIOUSLY TREATED WITH CHEMOTHERAPY

July 23, 2012

ADDITION OF TARCEVA® (ERLOTINIB) TO NEXAVAR® (SORAFENIB) DID NOT PROVIDE ADDITIONAL BENEFIT TO PATIENTS WITH UNRESECTABLE LIVER CANCER VERSUS NEXAVAR ALONE IN PHASE 3 TRIAL

Jun 28, 2012

FDA APPROVES OVERACTIVE BLADDER TREATMENT MYRBETRIQ™ (MIRABEGRON) FROM ASTELLAS

Jun 28, 2012

FULL PRESCRIBING INFORMATION FOR MYRBETRIQ (MIRABEGRON) EXTENDED RELEASE TABLETS

Jun 13, 2012

ASTELLAS SENDS 1,300 VOLUNTEERS TO ‘GIVE KIDS THE WORLD,’LARGEST SINGLE GROUP OF VOLUNTEERS IN VILLAGE HISTORY

Jun 12, 2012

ASTELLAS AND DNDI TO COLLABORATE ON NEW DRUG DISCOVERY RESEARCH FOR THE TREATMENT OF NEGLECTED TROPICAL DISEASES

Jun 06, 2012

MEDIVATION AND ASTELLAS PROVIDE UPDATE ON PREVAIL ENROLLMENT

Jun 04, 2012

ASTELLAS AND AMBIT INITIATE PHASE 2B DOSE FINDING STUDY OF QUIZARTINIB AS MONOTHERAPY IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Jun 04, 2012

GOVERNOR QUINN ANNOUNCES 150 NEW JOBS AT ASTELLAS HEADQUARTERS FOR THE AMERICAS IN ILLINOIS

Jun 04, 2012

AGENSYS AND SEATTLE GENETICS ANNOUNCE INTERIM PHASE I DATA FROM ASG-5ME CLINICAL TRIAL FOR PROSTATE CANCER

Jun 04, 2012

AVEO AND ASTELLAS ANNOUNCE TAURUS PATIENT PREFERENCE CLINICAL STUDY COMPARING TIVOZANIB WITH SUNITINIB IN FIRST-LINE KIDNEY CANCER

Jun 02, 2012

MEDIVATION AND ASTELLAS ANNOUNCE ENZALUTAMIDE DATA RELATING TO QUALITY OF LIFE MEASURES AND EXTENSION OF TIME TO FIRST SKELETAL-RELATED EVENT

May 30, 2012

MEDIVATION AND ASTELLAS ANNOUNCE INITIATION OF EXPANDED ACCESS PROGRAM FOR ENZALUTAMIDE (FORMERLY MDV3100) IN THE UNITED STATES

May 21, 2012

MEDIVATION AND ASTELLAS ANNOUNCE SUBMISSION OF NEW DRUG APPLICATION FOR ENZALUTAMIDE FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER IN PATIENTS PREVIOUSLY TREATED WITH CHEMOTHERAPY

May 21, 2012

ASTELLAS STATEMENT REGARDING NEW OVERACTIVE BLADDER GUIDELINES

May 18, 2012

MEDIVATION AND ASTELLAS ANNOUNCE ENZALUTAMIDE (FORMERLY MDV3100) DATA TO BEPRESENTED AT ASCO ANNUAL MEETING 2012

May 16, 2012

AVEO AND ASTELLAS ANNOUNCE POSITIVE FINDINGS FROM TIVO-1 SUPERIORITY STUDY OF TIVOZANIB IN FIRST LINE ADVANCED RCC

April 05, 2012

FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF MIRABEGRON - INVESTIGATIONAL OVERACTIVE BLADDER TREATMENT FROM ASTELLAS

March 13, 2012

ASTELLAS ONCOLOGY CYCLING TEAM DEBUTS WITH 12 RIDERS FOR 2012

February 21, 2012

ASTELLAS HIRES SENIOR VICE PRESIDENT OF NEW GLOBAL MEDICAL AFFAIRS ORGANIZATION

January 31, 2012

MEDIVATION AND ASTELLAS ANNOUNCE POSITIVE RESULTS FROM THE PHASE 3 AFFIRM TRIAL OF MDV3100 IN PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR CHEMOTHERAPY

January 06, 2012

ASTELLAS AND THERAVANCE ANNOUNCE TERMINATION OF LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR VIBATIV® (TELAVANCIN) FOR INJECTION

January 03, 2012

AVEO AND ASTELLAS ANNOUNCE TIVOZANIB SUCCESSFULLY DEMONSTRATED PROGRESSION-FREE SURVIVAL SUPERIORITY OVER SORAFENIB IN PATIENTS WITH ADVANCED RENAL CELL CANCER IN PHASE 3 TIVO-1 TRIAL

December 21, 2011

ZOGENIX AND ASTELLAS AGREE TO END CO-PROMOTION FOR SUMAVEL DOSEPRO EFFECTIVE MARCH 31, 2012

December 01, 2011

ASTELLAS ADDS TWO KEY SENIOR EXECUTIVES AT AGENSYS, INC.

November 11, 2011

ASTELLAS SIGNS UNITED NATIONS GLOBAL COMPACT

November 03, 2011

MEDIVATION AND ASTELLAS ANNOUNCE POSITIVE SURVIVAL DATA FROM INTERIM ANALYSIS OF PHASE 3 AFFIRM TRIAL OF MDV3100 IN MEN WITH ADVANCED PROSTATE CANCER

September 28, 2011

SEVEN CHICAGO AREA SERVICE PROJECTS TOP OFF CHANGING TOMORROW DAY AT ASTELLAS

August 28, 2011

ASTELLAS PHARMA INC.: ANNOUNCEMENT OF REGULATORY SUBMISSION FOR MIRABEGRON (YM178), A TREATMENT FOR OVERACTIVE BLADDER, IN U.S. AND EUROPE

August 15, 2011

ASTELLAS EXPANDS LEADERSHIP TEAM WITH SENIOR VICE PRESIDENT OF CORPORATE STRATEGY AND GOVERNMENT AFFAIRS

July 26, 2011

MERCK TO ACQUIRE RIGHTS TO VERNAKALANT I.V. IN CANADA, MEXICO AND THE UNITED STATES FROM ASTELLAS

June 06, 2011

ASTELLAS ANNOUNCES NEW STUDY RESULTS SHOWING INCREASED SURVIVAL RATE FOR METASTATIC PANCREATIC CANCER

June 03, 2011

TARCEVA NEARLY DOUBLED THE TIME PEOPLE WITH A GENETICALLY DISTINCT TYPE OF LUNG CANCER LIVED WITHOUT THEIR DISEASE GETTING WORSE

May 19, 2011

ASTELLAS ANNOUNCES VICE PRESIDENT OF SALES AND MARKETING FOR U.S. ONCOLOGY FRANCHISE

May 17, 2011

ASTELLAS ANNOUNCES POSITIVE PHASE III RESULTS SHOWING MIRABEGRON IMPROVES KEY OAB SYMPTOMS

May 03, 2011

ASTELLAS STRENGTHENS GLOBAL DEVELOPMENT TEAM

January 28, 2011

EARLY SUCCESSFUL READOUT OF TARCEVA STUDY IN A DISTINCT FORM OF LUNG CANCER

January 10, 2011

ASTELLAS TO REVIEW STRATEGIC BUSINESS ALTERNATIVES FOR PROSIDION SUBSIDIARY

November 16, 2010

2010 NSTA NEW SCIENCE TEACHER ACADEMY FELLOWS ANNOUNCED

November 02, 2010

ASTELLAS DONATES 150 LAPTOP COMPUTERS TO HELP INNER-CITY CHICAGO STUDENTS

ASTELLAS ANNOUNCES RETIREMENT OF DONALD RICE AND APPOINTMENT OF SEF KURSTJENS AS CEO AND PRESIDENT OF AGENSYS, INC.

October 28, 2010

NEW SURVEY SHOWS REAL-WORLD ACTIVITIES CAN HELP REINVIGORATE STUDENT INTEREST IN SCIENCE EDUCATION

September 27, 2010

LEXISCAN® (REGADENOSON) INJECTION STUDY IN SUBJECTS WITH ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PRESENTED AS LATE-BREAKER AT AMERICAN SOCIETY OF NUCLEAR CARDIOLOGY 2010

NEW SMARTPHONE APP LAUNCHES FOR CARDIAC IMAGING TEST

September 17, 2010

ASTELLAS MOBILIZES 1,300+ EMPLOYEES IN THE AMERICAS TO PARTICIPATE IN FIRST ANNUAL \'CHANGING TOMORROW DAY'

September 15, 2010

ASTELLAS AWARDS SCHOLARSHIPS TO 12 TRANSPLANT RECIPIENTS AND DONORS WHO EMBODY HOPE, COURAGE AND ACHIEVEMENT

September 15, 2010

ASTELLAS CELEBRATES THE MIRACLE OF TRANSPLANTATION BY SENDING FIVE RECIPIENTS TO THE 2011 ROSE PARADE®

September 1, 2010

AGENSYS, AN AFFILIATE OF ASTELLAS, ANNOUNCES INITIATION OF PHASE I CLINICAL TRIAL OF AGS-16M8F FOR RENAL CANCER

June 28, 2010

ASTELLAS ANNOUNCES ORAL PRESENTATION OF SGLT2 INHIBITOR DETAILING "SAFETY AND EFFICACY IN PATIENTS WITH TYPE 2 DIABETES AT THE "AMERICAN DIABETES ASSOCIATION MEETING

June 9, 2010

ASTELLAS COMPLETES ACQUISITION OF OSI PHARMACEUTICALS

June 8, 2010

ASTELLAS ANNOUNCES SUCCESSFUL COMPLETION OF TENDER OFFER FOR SHARES OF OSI

June 3, 2010

ASTELLAS ANNOUNCES SUCCESSFUL COMPLETION OF INITIAL TENDER OFFER FOR SHARES OF OSI AND ANNOUNCES SUBSEQUENT OFFER PERIOD

May 17, 2010

EXPIRATION DATE OF OSI OFFER EXTENDED TO JUNE 2, 2010

May 16, 2010

ASTELLAS PHARMA INC. TO ACQUIRE OSI PHARMACEUTICALS, INC.

May 03, 2010

NEW SCIENCE EDUCATION PROGRAM RESPONDS TO PRESIDENT\'S "CALL TO HELP YOUNG PEOPLE EXCEL IN SCIENCE

April 29, 2010

GOVERNOR QUINN ANNOUNCES ASTELLAS PHARMA U.S. "CHOOSES ILLINOIS FOR NEW HEADQUARTERS

April 29, 2010

OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA® RECEIVED APPROVAL IN THE EUROPEAN UNION "FOR MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER

April 26, 2010

OSI PHARMACEUTICALS ANNOUNCES THAT "RADIANT", AN INTERNATIONAL PHASE III TARCEVA "ADJUVANT TRIAL IN NON-SMALL CELL LUNG CANCER, COMPLETES ENROLLMENT

April 23, 2010

EXPIRATION DATE OF OSI OFFER EXTENDED TO MAY 17, 2010

April 16, 2010

FDA APPROVES TARCEVA AS A MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER

April 05, 2010

NUMBER OF AMERICANS WILLING TO DONATE ORGANS RISES, "BUT STILL NOT KEEPING PACE WITH NEED

March 31, 2010

EXPIRATION DATE OF OSI OFFER EXTENDED TO APRIL 23, 2010

March 29, 2010

ASTELLAS SIGNS CONFIDENTIALITY AGREEMENT WITH OSI

March 19, 2010

ASTELLAS ANNOUNCES CHANGES TO DIRECTOR NOMINEES FOR ELECTION TO OSI "PHARMACEUTICALS\' BOARD OF DIRECTORS

March 19, 2010

ASTELLAS ANNOUNCES EXPIRATION OF HSR WAITING PERIOD FOR OSI TENDER OFFER

March 19, 2010

OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA® RECEIVED A POSITIVE OPINION FROM HEALTH AUTHORITIES IN THE EUROPEAN UNION FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER

March 16, 2010

ASTELLAS ANNOUNCES FULL SLATE OF INDEPENDENT DIRECTOR NOMINEES FOR ELECTION AT OSI "PHARMACEUTICALS\' 2010 ANNUAL STOCKHOLDERS MEETING

March 15, 2010

ASTELLAS RESPONDS TO OSI PHARMACEUTICALS\' REJECTION

March 02, 2010

ASTELLAS PHARMA INC. COMMENCES TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES OF OSI PHARMACEUTICALS FOR $52 PER SHARE IN CASH

March 01, 2010

ASTELLAS PHARMA INC. OFFERS TO ACQUIRE OSI PHARMACEUTICALS FOR $52.00 PER SHARE IN CASH

January 15, 2010

FDA EXTENDS REVIEW PERIOD FOR TARCEVA APPLICATION FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER

January 13, 2010

SUMAVELTM DOSEPROTM AVAILABLE IN THE UNITED STATES TO TREAT ACUTE MIGRAINE AND CLUSTER HEADACHES

January 12, 2010

OSI PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND 2009 FULL YEAR TARCEVA SALES AT JP MORGAN HEALTHCARE CONFERENCE

December 29, 2009

U.S. PATENT AND TRADEMARK OFFICE GRANTS REISSUED PATENT REPLACING OSI PHARMACEUTICALS\' TARCEVA® COMPOSITION OF MATTER PATENT

December 16, 2009

FDA ADVISORY COMMITTEE RECOMMENDS AGAINST APPROVING TARCEVA FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER

December 07, 2009

ASTELLAS INDUCTED INTO NATIONAL MINORITY TRANSPLANT HALL OF FAME MOTTEP HONORS ASTELLAS FOR COMMITMENT TO TRANSPLANT COMMUNITY

November 16, 2009

OSI PHARMACEUTICALS ANNOUNCES TARCEVA TO BE REVIEWED BY THE FDA\'S ONCOLOGIC DRUGS "ADVISORY COMMITTEE FOR USE AS A FIRST-LINE MAINTENANCE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER

November 05, 2009

THERAVANCE AND ASTELLAS ANNOUNCE THE COMMERCIAL LAUNCH OF VIBATIVTM (telavancin) IN THE UNITED STATES

October 28, 2009

CARDIOME AND ASTELLAS ANNOUNCE INITIATION OF PATIENT ENROLMENT IN ACT 5 TRIAL

October 26, 2009

DONATE LIFE ILLINOIS, ASTELLAS AND THE CHICAGO BEARS PARTNER TO "TACKLE THE SHORTAGE IN HONOR OF BEARS LEGEND, WALTER PAYTON

October 22, 2009

ZOGENIX AND ASTELLAS ANNOUNCE DATA PUBLISHED SHOWING THE BENEFITS OF SUMAVELTM DOSEPROTM NEEDLE-FREE DELIVERY SYSTEM

October 02, 2009

NEW ANALYSIS SUPPORTS TOLERABILITY OF LEXISCAN® (regadenoson) INJECTION FOR PHARMACOLOGIC MYOCARDIAL PERFUSION IMAGING STUDIES

September 22, 2009

ASTELLAS AWARDS EDUCATIONAL SCHOLARSHIPS TO SIX TRANSPLANT RECIPIENTS WHO EMBODY THE SPIRIT OF GIVING BACK

September 21, 2009

ASTELLAS AND THE NATIONAL SCIENCE TEACHERS ASSOCIATION ANNOUNCE 2009 CLASS OF LOCAL SCIENCE EDUCATORS

September 17, 2009

U.S. PATENT AND TRADEMARK OFFICE ISSUES A NOTICE OF ALLOWANCE IN OSI PHARMACEUTICALS' REISSUE APPLICATION ON TARCEVA(R) COMPOSITION OF MATTER PATENT

September 15, 2009

ASTELLAS CELEBRATES THE MIRACLE OF TRANSPLANTATION BY SENDING FIVE RECIPIENTS TO THE 2010 ROSE PARADE®

September 11, 2009

THERAVANCE AND ASTELLAS ANNOUNCE FDA APPROVAL OF VIBATIV™ (telavancin) FOR THE TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

August 17, 2009

CHICAGO MAYOR HONORS ASTELLAS' EXCELLENCE IN LEARNING, DEVELOPMENT

August 13, 2009

UPDATE ON ASTELLAS' REQUEST FOR RIGOROUS TESTING AND SAFETY-RELATED LABELING FOR ANTI-REJECTION MEDICATIONS

August 10, 2009

ASTELLAS SEEKS RIGOROUS TESTING AND SAFETY-RELATED LABELING FOR ANTI-REJECTION MEDICATIONS UNIQUE NEEDS OF TRANSPLANT PATIENTSREQUIRE SPECIAL CARE TO PRESERVE THEIR GIFT OF LIFE

ADDITIONAL CLINICAL TRIAL TO BE CONDUCTED FOR KYNAPID UNDER FDA SPECIAL PROTOCOL AGREEMENT

August 1, 2009

NEW DATA FROM PHASE III SATURN STUDY SHOWED TARCEVA EXTENDED SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHEN USED IMMEDIATELY AFTER INITIAL CHEMOTHERAPY

July 13, 2009

NEW DATA FROM PHASE III SATURN STUDY SHOWED TARCEVA IMPROVED OVERALL SURVIVAL WHEN USED IMMEDIATELY AFTER INITIAL CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

July 6, 2009

OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF A TARCEVA(R) SUPPLEMENTAL NEW DRUG APPLICATION IN PANCREATIC CANCER FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION; TARCEVA'S SNDA IS GRANTED PRIORITY REVIEW DESIGNATION BY THE FDA

August 3, 2009

ZOGENIX AND ASTELLAS ENTER EXCLUSIVE CO-PROMOTION AGREEMENT IN THE US FOR NEWLY APPROVED SUMAVELTM DOSEPROTM

July 7, 2009

OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF A TARCEVA(R) SUPPLEMENTAL NEW DRUG APPLICATION IN PANCREATIC CANCER FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION; TARCEVA'S SNDA IS GRANTED PRIORITY REVIEW DESIGNATION BY THE FDA

June 25, 2009

ASTELLAS INFORMS CUSTOMERS OF MARKET WITHDRAWAL OF SPECIFIC PRODUCT LOTS

June 15, 2009

OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF TARCEVA SUPPLEMENTAL NEW DRUG APPLICATION FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION

June 04, 2009

ASTELLAS ADDS CNS THERAPY AREA LEADER TO GLOBAL R&D TEAM

June 01, 2009

ASTELLAS HIRES NEW VICE PRESIDENT OF COMPLIANCE

May 30, 2009

DATA FROM THE PHASE III ATLAS STUDY SHOW TARCEVA IN COMBINATION WITH AVASTIN AS FIRST-LINE MAINTENANCE THERAPY IMPROVED PROGRESSION-FREE SURVIVAL IN ADVANCED LUNG CANCER

May 28, 2009

ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF® (TACROLIMUS) IN CONJUNCTION WITH MYCOPHENOLATE MOFETIL (MMF) IN KIDNEY TRANSPLANT RECIPIENTS

May 28, 2009

ASTELLAS ANNOUNCES NEW VICE PRESIDENT OF MARKETING

May 28, 2009

PHASE 3 TRIAL INITIATED TO EVALUATE COMBINATION THERAPY OF NEXAVAR(R) AND TARCEVA(R) IN PATIENTS WITH LIVER CANCER

May 14, 2009

DATA FROM THE PHASE III SATURN STUDY SHOW TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL WHEN USED AS A FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER

April 1, 2009

ASTELLAS APPOINTS NEW US PRESIDENT AND CEO

March 31, 2009

ASTELLAS LAUNCHES VAPRISOL® (CONIVAPTAN HYDROCHLORIDE INJECTION) PREMIXED IN 5% DEXTROSE FOR THE TREATMENT OF HYPONATREMIA

March 19, 2009

OSI PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO THE FDA FOR TARCEVA AS A FIRST-LINE MAINTENANCE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER

March 16, 2009

ASTELLAS TO TERMINATE OFFER FOR CV THERAPEUTICS

March 6, 2009

ASTELLAS TO NOMINATE TWO DIRECTORS AND SUBMIT PROPOSAL TO REMOVE REMAINING FOUR DIRECTORS OF CV THERAPEUTICS

February 27, 2009

ASTELLAS FILES LAWSUIT AGAINST CV THERAPEUTICS

February 27, 2009

ASTELLAS COMMENCES TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES OF CV THERAPEUTICS FOR $16 PER SHARE IN CASH

February 23, 2009

ASTELLAS PHARMA ISSUES STATEMENT REGARDING CV THERAPEUTICS REJECTION OF ALL-CASH PROPOSAL

February 10, 2009

OSI PHARMACEUTICALS ANNOUNCES NOTIFICATION OF ANDA FILING FOR TARCEVA

February 2, 2009

PHASE III STUDY SHOWED TARCEVA IN COMBINATION WITH AVASTIN AS FIRST-LINE MAINTENANCE THERAPY IMPROVED PROGRESSION-FREE SURVIVAL IN ADVANCED LUNG CANCER

January 27, 2009

ASTELLAS PROPOSES TO ACQUIRE CV THERAPEUTICS FOR $16 PER SHARE IN CASH

November 26, 2008

TARCEVA® (ERLOTINIB) ENDORSED BY THE U.K.'S NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE FOR USE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

November 7, 2008

PHASE III STUDY (SATURN) SHOWED TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL AS A FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER

October 22, 2008

FDA APPROVES ASTELLAS' VAPRISOL® CONIVAPTAN HYDROCHLORIDE INJECTION) PREMIXED IN 5% DEXTROSE FOR THE TREATMENT OF HYPONATREMIA

October 14, 2008

ASTELLAS RIDE OF A LIFETIME CONTEST SENDS FIVE TRANSPLANT RECIPIENTS TO RIDE FLOAT IN 2009 ROSE PARADE®

October 06, 2008

GENENTECH AND OSI PHARMACEUTICALS ANNOUNCE TOPLINE RESULTS FROM PHASE III STUDY EVALUATING THE COMBINATION OF AVASTIN AND TARCEVA AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER

October 01, 2008

ASTELLAS JOINS FORCES WITH THE NATIONAL SCIENCE TEACHERS ASSOCATION TO SUPPORT LOCAL SCIENCE EDUCATORS

August 11, 2008

CARDIOME AND ASTELLAS ANNOUNCE RECEIPT OF FDA APPROVABLE LETTER FOR KYNAPIDTM

June 24, 2008

ASTELLAS LAUNCHES LEXISCANTM (REGADENOSON) INJECTION FOR USE AS A PHARMACOLOGIC STRESS AGENT IN RADIONUCLIDE MYOCARDIAL PERFUSION IMAGING (MPI)

April 10, 2008

CV THERAPEUTICS AND ASTELLAS ANNOUNCE FDA APPROVAL FOR LEXISCANTM (REGADENOSON) INJECTION

March 25, 2008

CIRCULATION PUBLISHES DATA SHOWING KYNAPID (VERNAKALANT HYDROCHLORIDE) INJECTION RAPIDLY CONVERTED SHORT-DURATION ATRIAL FIBRILLATION TO SINUS RHYTHM

Feburary 27, 2008

OSI PHARMACEUTICALS SEEKS TO STRENGTHEN TARCEVA PATENT BY FILING RE-ISSUE APPLICATION WITH THE U.S. PATENT AND TRADEMARK OFFICE

January 22, 2008

FDA APPROVES ADDITIONAL INDICATION FOR ASTELLAS MYCAMINE®

January 21, 2008

CARDIOME AND ASTELLAS ANNOUNCE REGULATORY UPDATE

December 14, 2007

OSI PHARMACEUTICALS ANNOUNCES LAUNCH DATE OF TARCEVA(R) (ERLOTINIB) IN JAPAN

December 11, 2007

FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF KYNAPID FOR ACUTE ATRIAL FIBRILLATION

November 7, 2007

STUDY SHOWS VERNAKALANT HYDROCHLORIDE IS EFFECTIVE IN CONVERSION TO NORMAL HEART RHYTHM IN ATRIAL FIBRILLATION PATIENTS FOLLOWING CARDIAC SURGERY

October 25, 2007

STUDY SHOWS VAPRISOL® IS EFFECTIVE IN INCREASING SERUM SODIUM LEVELS AND WELL-TOLERATED IN PATIENTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA

October 22, 2007

TARCEVA(R) (ERLOTINIB) EARNS APPROVAL FOR LUNG CANCER PATIENTS IN JAPAN

October 22, 2007

ADENOSCAN® PATENT LAWSUITS SETTLED

October 22, 2007

THERAVANCE RECEIVES FDA APPROVABLE LETTER FOR TELAVANCIN FOR THE TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

October 17, 2007

ASTELLAS PHARMA US, INC. AND THE INTERNATIONAL TRANSPLANT NURSES SOCIETY (ITNS) COLLABORATE ON CONTENT FOR TRANSPLANT EXPERIENCE PROGRAM

October 15, 2007

OSI PHARMACEUTICALS PROVIDES ADDITIONAL INFORMATION ABOUT US SALES OF TARCEVA

October 11, 2007

ASTELLAS RIDE OF A LIFETIME CONTEST SENDS FIVE TRANSPLANT RECIPIENTS TO RIDE FLOAT IN 2008 ROSE PARADE

September 18, 2007

OSI PHARMACEUTICALS ANNOUNCES PATENT TERM EXTENSION FOR TARCEVA(R) (ERLOTINIB)

September 7, 2007

OSI PHARMACEUTICALS SUMMARIZES DATA PRESENTED ON TARCEVA(R) (ERLOTINIB) AT THE 12TH WORLD CONGRESS ON LUNG CANCER MEETING

June 5, 2007

OSI PHARMACEUTICALS SUMMARIZES DATA ON TARCEVA(R) (ERLOTINIB) AT THE 2007 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING

April 25, 2007

OSI PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE III TARCEVA(R) STUDY PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY SHOWED SURVIVAL IMPROVEMENT IN PATIENTS WITH PANCREATIC CANCER

March 02, 2007

FDA APPROVES ASTELLAS VAPRISOL® FOR THE TREATMENT OF HYPERVOLEMIC HYPONATREMIA

February 26, 2007

Astellas Pharma US, Inc.'s "TRANSPLANT EXPERIENCE" PROGRAM RECEIVES NATIONAL RECOGNITION

February 19, 2007

CARDIOME AND ASTELLAS ANNOUNCE ACCEPTANCE OF NDA FOR REVIEW

January 29, 2007

OSI PHARMACEUTICALS ANNOUNCES EUROPEAN REGULATORY APPROVAL OF TARCEVA(R) FOR TREATMENT OF PATIENTS WITH PANCREATIC CANCER

November 15, 2006

OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA(R) RECEIVED POSITIVE OPINION FROM HEALTH AUTHORITIES IN EUROPEAN UNION FOR THE TREATMENT OF PATIENTS WITH PANCREATIC CANCER

September 21, 2006

OSI PHARMACEUTICALS LAUNCHES STUDY OF TARCEVA(R) AS ADJUVANT TREATMENT FOR NON-SMALL CELL LUNG CANCER

October 29, 2006

ASTELLAS PHARMA US, INC., GLAXOSMITHKLINE, AND VESIcare® (SOLIFENACIN SUCCINATE) SPONSOR THE #18 RACE CAR AT ATLANTA MOTOR SPEEDWAY TO RAISE AWARENESS ABOUT OVERACTIVE BLADDER

July 27, 2006

OSI PHARMACEUTICALS ANNOUNCES THAT ROCHE HAS RECEIVED NEGATIVE CHMP OPINION IN EUROPEAN UNION ON TARCEVA(R) IN PANCREATIC CANCER

July 25, 2006

STUDY DEMONSTRATES IMPROVED RENAL FUNCTION AND LIPID VALUES IN KIDNEY TRANSPLANT PATIENTS ON PROGRAF ® COMPARED TO PATIENTS TAKING NEORAL ®

June 6, 2006

OSI SUMMARIZES CLINICAL DATA ON TARCEVA(R) AT THE 2006 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING

June 5, 2006

RESULTS FROM A RANDOMIZED PHASE II TRIAL SUGGESTED THE COMBINATIONS OF AVASTIN(R) PLUS TARCEVA(R) AND AVASTIN PLUS CHEMOTHERAPY IMPROVED PROGRESSION- FREE SURVIVAL IN ADVANCED NON-SMALL CELL LUNG CANCER

April 26, 2006

ASTELLAS LAUNCHES VAPRISOL® FOR THE TREATMENT OF EUVOLEMIC HYPONATREMIA IN HOSPITALIZED PATIENTS

April 17, 2006

OSI PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR TARCEVA(R) IN JAPAN

April 3, 2006

ASTELLAS TO ACQUIRE AMEVIVE® (ALEFACEPT)

April 1, 2006

ASTELLAS RECEIVES FDA APPROVAL OF PROGRAF® (TACROLIMUS) FOR USE IN HEART TRANSPLANT RECIPIENTS

March 31, 2006

NEW DRUG APPLICATION SUBMITTED FOR RSD1235

Feburary 1, 2006

OSI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER NET SALES FOR TARCEVA(R)'S INTERNATIONAL LAUNCH; TARCEVA WORLD-WIDE SALES REACHED $309 MILLION IN 2005

January 19, 2006

ASTELLAS EDUCATES AND INFORMS PHYSICIANS AND PATIENTS ON CHANGES TO PROTOPIC LABEL IN U.S.

January 11, 2006

OSI PHARMACEUTICALS ANNOUNCES NET U.S. TARCEVA(R) SALES FOR FOURTH QUARTER AND YEAR-END 2005; NARROWS MACUGEN(R) GUIDANCE & UPDATES CASH POSITION ON BALANCE SHEET

December 30, 2005

FDA APPROVES ASTELLAS' VAPRISOL® FOR THE TREATMENT OF EUVOLEMIC HYPONATREMIA

November 7, 2005

THERAVANCE AND ASTELLAS TO COLLABORATE ON TELAVANCIN, INVESTIGATIONAL ANTIBIOTIC FOR SERIOUS INFECTIONS

November 3, 2005

MULTIMEDIA NEWS RELEASE -- FDA APPROVES TARCEVA(R) IN COMBINATION WITH GEMCITABINE CHEMOTHERAPY FOR TREATMENT OF LOCALLY ADVANCED, INOPERABLE OR METASTATIC PANCREATIC CANCER

November 2, 2005

FDA APPROVES TARCEVA(R) IN COMBINATION WITH GEMCITABINE CHEMOTHERAPY FOR TREATMENT OF LOCALLY ADVANCED, INOPERABLE OR METASTATIC PANCREATIC CANCER; TARCEVA NOW APPROVED FOR ADVANCED NON-SMALL CELL LUNG CANCER AND PANCREATIC CANCER

October 19, 2005

CARDIOME AND ASTELLAS INITIATE ACT 4 STUDY

October 12, 2005

OSI REITERATES CONFIDENCE IN TARCEVA

September 21, 2005

OSI PHARMACEUTICALS ANNOUNCES TARCEVA(R) GRANTED APPROVAL IN THE EUROPEAN UNION FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

September 13, 2005

FDA ADVISORY PANEL RECOMMENDS TARCEVA(R) APPROVAL FOR PANCREATIC CANCER; COMMITTEE SUPPORTS NEW INDICATION FOR EGFR INHIBITOR TARCEVA

August 10, 2005

RAGADENOSON MEETS PRIMARY ENDPOINT IN FIRST PHASE 3 TRIAL

August 8, 2005

OSI PHARMACEUTICALS ANNOUNCES TARCEVA(R) TO BE REVIEWED BY THE FDA'S ONCOLOGIC DRUGS ADVISORY COMMITTEE FOR USE IN PANCREATIC CANCER

July 13, 2005

OSI PHARMACEUTICALS ANNOUNCES TARCEVA GRANTED APPROVAL IN CANADA FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

June 27, 2005

OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA-R- RECEIVES POSITIVE OPINION IN EU FOR THE TREATMENT OF PATIENTS WITH ADVANCED LUNG CANCER

June 2, 2005

OSI PHARMACEUTICALS ANNOUNCES ISSUANCE OF ADDITIONAL U.S. PATENT FOR TARCEVA; EXTENDS PATENT EXCLUSIVITY

May 24, 2005

THREE CLINICAL STUDIES DEMONSTRATE ONCE-DAILY MODIFIED RELEASE PROGRAF® FORMULA TO BE PROMISING TREATMENT OPTION

May 24, 2005

NEW STUDIES OF IMMUNOSUPPRESSIVE REGIMENS LIMITING OR AVOIDING THE USE OF STEROIDS SHOW EXCELLENT GRAFT SURVIVAL IN TRANSPLANT RECIPIENTS ON A PROGRAF®-BASED (TACROLIMUS) REGIMEN

May 17, 2005

DATA FROM TARCEVA CLINICAL TRIAL PROGRAM PRESENTED AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

May 16, 2005

DATA FROM TARCEVA-TM- CLINICAL TRIAL PROGRAM PRESENTED AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING; EGFR AMPLIFICATION / MUTATION ANALYSIS FROM THE REGISTRATION BR.21 TRIAL PRESENTED

May 14, 2005

PHASE III STUDY OF TARCEVA IN COMBINATION WITH CHEMOTHERAPY IMPROVES SURVIVAL IN PANCREATIC CANCER PATIENTS

May 13, 2005

ANTI-FUNGAL AGENT MYCAMINETM AVAILABLE TO PHYSICIANS

May 2, 2005

OSI PHARMACEUTICALS AND GENENTECH ANNOUNCE FILING OF A SUPPLEMENTAL NEW DRUG APPLICATION TO THE FDA FOR TARCEVA -TM- IN PANCREATIC CANCER

April 1, 2005

YAMANOUCHI, FUJISAWA UNITE TO FORM ASTELLAS PHARMA US, INC., NORTH AMERICAN HEADQUARTERS TO BE IN CHICAGO

March 22, 2005

OSI PHARMACEUTICALS ANNOUNCES TARCEVA GRANTED FIRST EUROPEAN APPROVAL IN SWITZERLAND; FIRST AND ONLY AGENT APPROVED IN ITS CLASS TO SHOW A SURVIVAL BENEFIT

January 27, 2005

DATA FROM PHASE III STUDY SHOW TARCEVA PLUS GEMCITABINE SIGNIFICANTLY IMPROVES SURVIVAL COMPARED TO GEMCITABINE ALONE IN ADVANCED PANCREATIC CANCER PATIENTS

November 22, 2004

OSI PHARMACEUTICALS ANNOUNCES LAUNCH OF TARCEVA-TM

November 18, 2004

FDA APPROVES TARCEVA-TM- FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER; ONLY TARGETED EGFR THERAPY SHOWN TO IMPROVE SURVIVAL IN ADVANCED NON-SMALL CELL LUNG CANCER

September 30, 2004

OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF TARCEVA NEW DRUG APPLICATION FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION

September 20, 2004

TARCEVA PLUS GEMCITABINE IMPROVES SURVIVAL COMPARED TO GEMCITABINE ALONE IN FIRST-LINE PANCREATIC CANCER PATIENTS

September 10, 2004

GENENTECH AND OSI PHARMACEUTICALS INITIATE PHASE IIIB CLINICAL TRIAL OF TARCEVA IN ADVANCED NON-SMALL CELL LUNG CANCER

August 26, 2004

OSI PHARMACEUTICALS ANNOUNCES ROCHE FILING OF TARCEVA -TM- MARKETING APPLICATION WITH EUROPEAN HEALTH AUTHORITIES

August 2, 2004

OSI PHARMACEUTICALS AND GENENTECH ANNOUNCE COMPLETION OF NEW DRUG APPLICATION FOR FDA APPROVAL OF TARCEVA

June 29, 2004

OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA HAS BEEN ACCEPTED INTO THE FDA'S PILOT 1 PROGRAM

July 16, 2004

OSI PHARMACEUTICALS AND GENENTECH ENTER INTO CO-PROMOTION AND MANUFACTURING AGREEMENTS FOR TARCEVA

June 5, 2004

EARLY CLINICAL DATA EVALUATING THE COMBINATION OF AVASTIN AND TARCEVA YIELD INITIAL PROMISING RESULTS IN SEVERAL CANCERS

April 26, 2004

TARCEVA EXTENDS SURVIVAL OF PATIENTS WITH RELAPSED NON-SMALL CELL LUNG CANCER
March 19, 2004 OSI PHARMACEUTICALS INITIATES PHASE II STUDY OF TARCEVA IN NON-SMALL CELL LUNG CANCER PATIENTS WITH POOR PERFORMANCE STATUS

January 21, 2004

OSI PHARMACEUTICALS INITIATES 'ROLLING' SUBMISSION OF A NEW DRUG APPLICATION WITH THE FDA FOR TARCEVA-TM- IN NON-SMALL CELL LUNG CANCER

November 11, 2003

OSI PHARMACEUTICALS INITIATES PHASE II 'DOSE-TO-RASH' DOSE ESCALATION STUDY FOR TARCEVA--ERLOTINIB HCL--

October 1, 2003

PHASE III TRIALS OF TARCEVA PLUS CHEMOTHERAPY IN FIRST-LINE NON-SMALL CELL LUNG CANCER DO NOT MEET PRIMARY EFFICACY ENDPOINT

August 8, 2003

TARCEVA -- ERLOTINIB HCL -- PHASE II CLINICAL TRIAL INITIATED IN PATIENTS WITH MALIGNANT GLIOMA

June 3, 2003

OSI SUMMARIZES KEY CLINICAL DATA FOR TARCEVA - ERLOTINIB HCL - PRESENTED AT ASCO

May 31, 2003

TARCEVA -- ERLOTINIB HCL -- SHOWS ENCOURAGING SAFETY PROFILE AND ACTIVITY IN PHASE I CLINICAL STUDY IN PATIENTS WITH MALIGNANT GLIOMA

April 10, 2003

OSI PHARMACEUTICALS UPDATES INVESTORS ON STATUS OF TARCEVA DEVELOPMENT PROGRAM

January 30, 2003

OSI PHARMACEUTICALS ANNOUNCES TARCEVA INTERNATIONAL PHASE III REFRACTORY / ADVANCED NON-SMALL CELL LUNG CANCER CLINICAL TRIAL HAS REACHED ITS TARGET ENROLLMENT GOAL

January 28, 2003

OSI PHARMACEUTICALS ANNOUNCES TARCEVA; INTERNATIONAL PHASE III PANCREATIC CANCER CLINICAL TRIAL HAS REACHED ITS TARGET ENROLLMENT GOAL

September 23, 2002

OSI PHARMACEUTICALS RECEIVES SECOND FDA FAST-TRACK DESIGNATION FOR TARCEVA; ANNOUNCES AMENDMENTS TO TARCEVA DEVELOPMENT PLAN

September 12, 2002

INTERNATIONAL TRIAL EVALUATING TARCEVA IN LUNG CANCER COMPLETES PATIENT ENROLLMENT

August 19, 2002

OSI PHARMACEUTICALS AND GENENTECH PROVIDE UPDATE ON STATUS OF TARCEVA ROGRAM

August 1, 2002

TARCEVA U.S. PHASE III NON-SMALL CELL LUNG CANCER CLINICAL TRIAL COMPLETES PATIENT ENROLLMENT

May 14, 2002

GENENTECH AND OSI PHARMACEUTICALS ANNOUNCE FDA FAST-TRACK DESIGNATION FOR TARCEVA

May 2, 2002

OSI PHARMACEUTICALS ANNOUNCES COMPLETION OF INITIAL COHORT IN PHASE III PANCREATIC CANCER TRIAL FOR TARCEVA
   
 
Copyright © 2005 - 2013 Astellas Pharma US, Inc. Site Map  Privacy Policy   Legal Disclaimer  Contact Us